Quotient Ltd  

(Public, NASDAQ:QTNT)   Watch this stock  
Find more results for QTNT
-0.21 (-4.76%)
Real-time:   2:53PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.17 - 4.58
52 week 2.78 - 7.74
Open 4.47
Vol / Avg. 360,868.00/620,113.00
Mkt cap 191.35M
P/E     -
Div/yield     -
EPS -2.28
Shares 45.59M
Beta 0.74
Inst. own 89%
Feb 14, 2018
Quotient Ltd at Leerink Partners Global Healthcare Conference
Feb 6, 2018
Q3 2018 Quotient Ltd Earnings Call
Jan 11, 2018
Quotient Ltd at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -346.66% -382.73%
Operating margin -291.77% -333.19%
EBITD margin - -290.63%
Return on average assets -62.67% -74.06%
Return on average equity - -751.76%
Employees 406 -
CDP Score - -


28 Esplanade
+44-131-4456159 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Officers and directors

Paul E. Cowan Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Edward Farrell President
Age: 45
Bio & Compensation  - Reuters
Jeremy Stackawitz President
Age: 40
Bio & Compensation  - Reuters
Christopher J. Lindop Chief Financial Officer, Principal Financial Officer
Age: 58
Bio & Compensation  - Reuters
Roland Boyd Group Financial Controller, Treasurer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Heino von Prondzynski Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Sarah A. O'Connor Director
Age: 54
Bio & Compensation  - Reuters
Zubeen Shroff Director
Age: 49
Bio & Compensation  - Reuters
John Wilkerson Director
Age: 70
Bio & Compensation  - Reuters
Thomas A. Bologna Independent Director
Age: 66
Bio & Compensation  - Reuters